All studies
CompletedPhase IIInterventional

Hereditary Sensory Neuropathy Serine trial (SENSE trial)

Hereditary sensory neuropathy type 1 (HSN1) is a rare genetic condition that damages the peripheral nerves. Over time, it causes numbness, pain, and muscle weakness in the hands, feet, and legs. At present, there is no cure or approved treatment to stop it from getting worse. The SENSE trial is looking at whether taking an amino acid supplement called L-serine can protect nerves and slow down disease progression. Researchers at Queen Square in London are comparing L-serine against an inactive dummy treatment (placebo) over 12 months. Adults aged 18 and older with genetically confirmed HSN1 may be able to take part. The study involves five check-ups (four hospital visits and one phone call) and includes leg MRI scans, blood tests, and routine nerve checks. The results could help doctors find the first effective treatment for HSN1.

At a glance

Status
Completed
Phase
Phase II
Sponsor
University College London
Enrolment target
50
Start
01 Aug 2023
Estimated completion
30 Aug 2024

What is this study about?

Hereditary sensory neuropathy type 1 (HSN1) is an inherited condition affecting the peripheral nerves—the body's wiring system that carries messages between the brain, spinal cord, and limbs. People living with HSN1 gradually lose sensation and may feel burning nerve pain or muscle weakness, particularly in their feet and hands. Because there are currently no treatments that can stop or slow this nerve damage, finding a therapy that protects nerve cells is a high priority.

This clinical trial is testing a natural amino acid supplement called L-serine. In earlier small studies, L-serine showed encouraging signs that it might help slow down nerve deterioration in people with HSN1 caused by changes in the SPTLC1 or SPTLC2 genes. The SENSE study is designed to give doctors clear, reliable answers by testing L-serine against a dummy treatment (placebo) in a carefully controlled 12-month study.

Researchers are also using specialised MRI scans of the lower legs to measure muscle changes, such as fat replacing muscle tissue over time. If these scans prove successful, they will provide a gentle, non-invasive way for doctors to track whether treatments are working in future care and clinical research.

By taking part, participants will play an essential role in advancing knowledge about this rare condition. The findings could pave the way for the first licensed treatment for HSN1, offering better long-term support for patients and families across the UK and worldwide.

Key takeaways

  • The SENSE trial tests whether the supplement L-serine can protect nerves in adults with HSN1.
  • Participation lasts 12 months and involves four hospital visits in London and one phone call.
  • Half of the participants will receive L-serine, and the other half will receive an inactive dummy treatment (placebo).
  • Tests include leg MRI scans, blood tests, nerve checks, and optional skin biopsies.
  • Joining is completely voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is open to adults aged 18 and over who have a confirmed genetic diagnosis of HSN1 linked to the SPTLC1 or SPTLC2 gene. Participants need to be able to complete standard nerve and mobility checks with the clinical team and must be able to have an MRI scan without needing medication to relax.

Because scientists do not yet know whether L-serine is safe during pregnancy, female participants who could become pregnant must use a reliable method of contraception throughout the trial and for a short time after finishing. You cannot take part if you are currently pregnant or breastfeeding.

You will not be able to join if you have had foot surgery in the past six months or have an operation planned during the trial year. People with type 1 or type 2 diabetes, a history of kidney stones, another nerve or muscle condition, or metal implants that make MRI scans unsafe are also unable to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have a confirmed genetic diagnosis of HSN1 (SPTLC1 or SPTLC2 gene).
  3. I can safely have an MRI scan (no incompatible metal implants or severe claustrophobia).
  4. I do not have diabetes or a history of kidney stones.
  5. I have not had foot surgery in the last six months and do not plan to have foot surgery this year.
  6. I am not pregnant or breastfeeding, and I am willing to use reliable contraception if required.
Answer every question to see your result.

What does participation involve?

Taking part in the trial lasts for approximately 12 months. During this time, you will have five appointments: four in-person visits to the Queen Square Centre for Neuromuscular Diseases in London and one review over the phone.

At your hospital visits, the team will carry out health checks, ask you to complete quality-of-life questionnaires, and take blood samples. You will have lower-leg MRI scans and standard nerve conduction tests, which use small sticky pads on the skin to measure nerve signals. You may also be invited to have two tiny skin samples (biopsies) taken from your thigh under local anaesthetic.

You will be randomly assigned to receive either L-serine or a placebo (a dummy powder or liquid that looks and tastes identical). A computer decides your group by chance. Neither you nor your study doctor will know which treatment you are taking, but your doctor can check immediately if there is ever a medical emergency.

Potential risks and benefits

Taking part may not directly improve your symptoms, but you will be helping researchers discover whether L-serine can slow down HSN1 for future patients. L-serine is a widely studied supplement and is generally well-tolerated. Minor side effects such as mild nausea or brief muscle twitches are rare and have usually only occurred at much higher doses than those used in this trial. Common procedures like MRI scans can feel noisy or enclosed, and blood tests or skin biopsies can cause brief stinging or mild bruising. Your care team will monitor you closely at every visit. Taking part is completely voluntary, and you are free to leave the trial at any time without giving a reason and without your normal NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • National Hospital for Neurology & Neurosurgery
    City only
    London, England

Common questions

What is L-serine?

L-serine is a naturally occurring amino acid (a building block of protein) that plays an important role in nerve health and metabolism.

What is a placebo and why is it used?

A placebo is an inactive substance that looks and tastes like the real supplement. Comparing L-serine to a placebo helps researchers prove whether any health improvements are genuinely caused by the treatment.

Will I have to pay to take part?

No, the trial treatment and all study tests are provided free of charge. You can ask the study team whether help is available for your travel expenses to London.

Are MRI scans safe?

Yes. MRI scans use magnetic fields rather than radiation (X-rays) to take pictures of your muscles. Earplugs are provided because the scanner can be loud.

Can I leave the study if I change my mind?

Yes. You are free to withdraw from the trial at any point, and your decision will not affect your relationship with your healthcare team or your routine NHS treatment.

How to find out more

Mary Reilly

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.